AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
AnaptysBio, Inc. (ANAB)
Last anaptysbio, inc. earnings: 3/2 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anaptysbio.com/investor-relations
Company Research
Source: GlobeNewswire
Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with primary advanced or recurrent endometrial cancer First-in-class pivotal data in endometrial cancer, if approved, to be a potential significant driver of JEMPERLI royalties to AnaptysBio SAN DIEGO, Dec. 02, 2022 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK’s RUBY/ENGOT-EN6/GOG3031/NSGO Phase 3 trial of JEMPERLI (dostarlimab) plus standard of care chemotherapy compared to chemotherapy plus placebo in patients with primary advanced or recurrent endometrial cancer, met its primary endpoint of investigator-assessed progression-free survival (PFS). The JEMPERLI regimen showed a statistically significant and clinically meaningful benefit in the prespecified mismatch repair deficient (dMMR)/microsatellite instabili
Show less
Read more
Impact Snapshot
Event Time:
ANAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANAB alerts
High impacting AnaptysBio, Inc. news events
Weekly update
A roundup of the hottest topics
ANAB
News
- AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $34.00 price target on the stock.MarketBeat
- AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]Yahoo! Finance
- Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]Yahoo! Finance
- Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) [Yahoo! Finance]Yahoo! Finance
- Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties [Yahoo! Finance]Yahoo! Finance
ANAB
Earnings
- 5/9/24 - Miss
ANAB
Sec Filings
- 5/9/24 - Form 10-Q
- 5/9/24 - Form 8-K
- 5/6/24 - Form SC
- ANAB's page on the SEC website